Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell ly...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:N Engl J Med
Hoofdauteurs: Wang, Michael L., Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J., Chang, Betty Y., Beaupre, Darrin M., Kunkel, Lori A., Blum, Kristie A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4513941/
https://ncbi.nlm.nih.gov/pubmed/23782157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1306220
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items